ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2024
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism.
Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review.CNS drugs · 2023Pooled it
- Synthesis and Biological Evaluation of 4‑Bromo-ACS omega · 2026Article
- Rapid antidepressant potential of nitrous oxide: current state and major questions.Molecular psychiatry · 2026Review
- Prevalence, types, and demographic characteristics associated with major life changes following psychedelic use.Scientific reports · 2026Article
- Molecules, meaning, and physiology: disentangling the active ingredients of psychedelic therapeutics.Frontiers in neuroscience · 2026Article
- Determination and Confirmation of Psychedelic and Psychoactive Compounds in Botanical Materials by UPLC-ESI-MS/MS: Single-Laboratory Validation.Journal of AOAC International · 2026Article
- Recalled childhood trauma and post-psychedelic trajectories of change in a mixed-methods study.Scientific reports · 2025Article
- A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder.Brain sciences · 2025Review
- The impact of the serotonergic psychedelic DOI on active vision in freely moving mice.bioRxiv : the preprint server for biology · 2025Article
- Is there a place for psychedelics in sports practice?Acta neuropsychiatrica · 2025Review
- The serotonergic psychedelic DOI impairs deviance detection in the auditory cortex.Journal of neurophysiology · 2025Article
- Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.Addiction (Abingdon, England) · 2025Article
- Virtual reality and psychedelics: new perspectives and new possibilities in the treatment of alcohol use disorder.Frontiers in psychiatry · 2025Review
- The serotonergic psychedelic DOI impairs deviance detection in the auditory cortex.bioRxiv : the preprint server for biology · 2024Article
- Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study.Scientific reports · 2024Article
- Psilocybin-assisted therapy and HIV-related shame.Scientific reports · 2024Article
- A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials.Npj mental health research · 2024Review
- Structural characterization and comparative analysis of polymorphic forms of psilocin (4-hy-droxy-Acta crystallographica. Section E, Crystallographic communications · 2024Article
- Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ).Journal of psychopharmacology (Oxford, England) · 2024Article
- Review
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical investigation of psychedelic medicines has blossomed over the last 5 years. Data from a Phase 3 industry trial and a multicenter Phase 2 industry trial, in addition to multiple early phase investigator-initiated and industry trials, have now been published in peer-reviewed journals. This narrative review summarizes both the recent data and the current clinical trials that are being conducted with various classes of "psyche-manifesting" substances, which may prove beneficial in the treatment of a broad range of conditions. Methodological considerations, unique challenges, and next steps for research are discussed in keeping with the uniquely "experiential" nature of these therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.